Interim report q1 2017 – Regulatory
This press release may not be published or distributed, directly or indirectly, in or into the united states, Canada, Japan, Australia, Hong kong, Switzerland, Singapore, south Africa or New Zealand or in any other jurisdiction where distribution of this press release would be subject to legal restrictions.
Hemcheck Sweden AB (publ) announces today that the company will publish the interim report for the first quarter of 2017. Selected parts of the report can be found below. The report in its entirety is available to download on the company’s website www.hemcheck.se.
If hemCheck
Hemcheck Sweden AB (publ) develops and commercializes a unique product concept, Helge(TM) for point-of-care detection of hemolysis. Hemolysis, broken red blood cells, is the most common cause of blood samples can not be analyzed. This leads to worse care, the risks for the patients and high costs for society. Helge(TM) detect the presence of hemolyzed blood samples in direct connection to the sampling, and thus contribute to improved care for patients around the world. hemChecks the company is headquartered in Karlstad, Sweden.
Contact
Hemcheck Sweden AB (publ)
Annelie Brolinson, managing director
Tel: +46 70 288 0826
E-mail: annelie.brolinson@hemcheck.com
Yliopistonkatu 2
651 88 Karlstad, sweden
www.hemcheck.see
Important information
This information is such information that hemCheck is obliged to publish
according to the EU’s marknadsmissbruksförordning. The information was submitted, by the above
contact person in the government, for publication on 12th may 2017 there is 08:30
Summary of the interim report, 1 January – 31 march 2017
-
Operating income amounted to sek 10 thousand (17 thousand)
-
Profit after financial items -1 797 thousand (-455 thousand)
-
Earnings per share 0.16 for sek (loss: 0.04 kr)
Significant events during the first quarter of
In January received hemCheck european approval in respect of one of the company’s key patents. The validation procedure is now under way in a number of selected countries in Europe.
The company carried out in February to a successful issue a total of $ 30 180 thousand before issue costs.
The company’s shares were issued on 15 march for trading on First North under the ticker symbol “HEMC”.
Significant events after the reporting period
hemCheck has recruited a product manager, Eva-Lotta Palm, with many years of experience from the pharmaceutical industry where she worked with research and development. The tasks will mainly include the verification work with the aim of finalizing the product concept, Helge consisting of one-time test as well as the readers.
CEO comments
The first quarter of 2017 has been the most eventful in the company’s history. Work with the listing on First North, was a great and important step to secure the economic conditions to proceed with the development of our product concepts. The outcome of the funding was successful, and in addition to capital, we have also been able to attract competent investors to the company.
Activities during the quarter continued according to plan. The reader has taken shape and is now available as a prototype with all the basic tasks that the final product shall have. We are now working internally to further develop and verify the reader and engångstestet. We have also shown the prototype of the reader for our användarpanel, consisting of a group of nurses. Their feedback was positive and we take with us their important views into the final phase of product development.
In addition to the comprehensive testing that is ongoing at the central hospital in Karlstad has engångstestet now also been tested by a small group of nurses at the emergency department in Kalmar. The response was good even from this group of users.
The objective to prepare the product concept, Helge, consisting of one-time test, and the readers, for CE-marking in 2017/18 remain and we are working focused to this. We have also hired a laboratoriechef to meet the increasing workload in all of our projects.
Another positive event during the quarter that has passed was that the EPO announced the approval of one of our key product patents. We have now vidarefört patent was filed in the subsequent validation phase.
In the march participated hemCheck at an international conference fully dedicated to the preanalytiska phase. The conference, which this year attracted a record number of visitors, is organized by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). The theme this year was “the Improvement of the quality of the preanalytiska phase through programming and testing” which is exactly the hemCheck work with when we develop a point-of-care tests of blood samples. A clear evidence on the relevance of our work.
In order to identify how hemolysis is perceived by the market has hemCheck conducted extensive market research in sweden and sjukhuslaboratorier in Sweden and in the Netherlands. The latter conducted in cooperation with Business Sweden. The market research shows that hemolysis is perceived as a significant problem both in emergency rooms and laboratories, then it delays the test results of 30-60 minutes, impairs the patient flows, leading to unnecessary suffering for patients and increased costs for health care services. To detect hemolysis in an early stage solves several problems for the emergency room, and easy methods to reduce hemolysfrekvensen demand therefore. Above all, highlights the benefits that the patient will not need to undergo a further thyroid blood tests and the clinic, saving valuable time when the patient does not need to be on which improves patient flows significantly. The above-mentioned problems would be solved if the care provider had access to a user-friendly and affordable method to find the hemolysis directly on the hplc.
Karlstad in may
Annelie Brolinson
CEO
Company information
Hemcheck Sweden AB (publ)
Corporate identity number: 556811-5272
Legal form: Public limited company
Address: Yliopistonkatu 2, 656 37 Karlstad, Sweden
Telephone: +46 (0)702 88 08 26
Website: www.hemcheck.com
Financial statements in the future
Interim report 1 January – 30 June 2017; will be published on 28 August
Interim report 1 January – 30 september 2017; published October 30,
Q1 2017_FINAL
